Professor of Medicine University of Michigan Ann Arbor, Michigan, United States
Disclosure(s):
Robert J. Fontana, MD: No relevant disclosure to display
1. Chen VL, Morgan TR, Rotman Y, et al. Resmetirom therapy for MASLD: October 2024 updates to AASLD Practice Guideline. Hepatology 2025: 81: 312-320 2. Kanwal F, Neuschwander-Tetri, BA, et al. MASLD: Update and impact of new nomenclature on the AASLD practice guidance on NAFLD. Hepatology 2024; 79: 1212-1219. 3. Sterling RK, Patel K, et al. AASLD Practice Guidelines on blood-based non-invasive liver disease assessment of hepatic fibrosis and steatosis. Hepatology 2025: 81: 321-357.
Learning Objectives:
1. Increased awareness of the epidemiology and clinical manifestations of MASLD
2. Understand how to diagnose and stage liver disease severity in patients with MASLD
3. Know what the current recommendations and treatments are for patients with MASLD.
